Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 7/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | ABL1 | P00519 | 4/20 | 0.38 |
| ▸ | HCK | P08631 | 1/20 | 0.38 |
| ▸ | FRK | P42685 | 1/20 | 0.38 |
| ▸ | BLK | P51451 | 1/20 | 0.38 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.38 |
| ▸ | ABL2 | P42684 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552990 | 1.00 | ESR2 (0.48) | ESR2NR1H2TGFBR1PIK3CDSRC | |
| SCHEMBL21528189 | 0.89 | ESR2 (0.46) | ESR2NR1H2TGFBR1SRCABL1 | |
| SCHEMBL31046975 | 0.89 | ESR2 (0.46) | ESR2NR1H2TGFBR1SRCABL1 | |
| SCHEMBL23150435 | 0.87 | PIK3CD (0.43) | PIK3CDSRCEGFRBLKPIK3CG | |
| SCHEMBL29867706 | 0.86 | PIK3CD (0.39) | PIK3CDSRCEGFRPIK3CG | |
| SCHEMBL20553360 | 0.82 | MTOR (0.58) | TGFBR1PIK3CDABL1PIK3CG | |
| SCHEMBL30740011 | 0.82 | MTOR (0.58) | TGFBR1PIK3CDABL1PIK3CG | |
| SCHEMBL29867929 | 0.82 | MTOR (0.58) | TGFBR1PIK3CDABL1PIK3CG | |
| SCHEMBL20553139 | 0.81 | TGFBR1 (0.54) | TGFBR1PIK3CDSRCEGFRABL1 | |
| SCHEMBL31046938 | 0.81 | TGFBR1 (0.54) | TGFBR1PIK3CDSRCEGFRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3788050-B1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240174615-A1 | SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-30 | — | — | US | disclosed |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| EP-4320101-A2 | SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS | Revolution Medicines, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4168002-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3788049-B1 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230055672-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-02-23 | — | — | US | disclosed |
| US-20220340596-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2022-10-27 | — | — | US | disclosed |
| WO-2022216900-A2 | SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS | Revolution Medicines, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | ESR2 1795/4885NR1H2 3013/4885TGFBR1 3678/4885 |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | ESR2 2077/4885NR1H2 3048/4885TGFBR1 3567/4885 |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | ESR2 1795/4885NR1H2 3013/4885TGFBR1 3678/4885 |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | ESR2 1795/4885NR1H2 3013/4885TGFBR1 3678/4885 |
| US-20240174615-A1 | SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS | MLST8, MTOR, RICTOR | ESR2 2865/4885NR1H2 3344/4885TGFBR1 4083/4885 |
| US-20220340596-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | ESR2 1795/4885NR1H2 3013/4885TGFBR1 3678/4885 |
| US-20230055672-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | ESR2 2077/4885NR1H2 3048/4885TGFBR1 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.